INTS · CIK 0001567264 · operating
Intensity Therapeutics is a late-stage clinical biotechnology company developing cancer treatments targeting regional and systemic disease. The company's primary asset is INT230-6, a product candidate being evaluated in Phase 3 clinical trials for soft tissue sarcoma and in Phase 2 trials for neoadjuvant and metastatic triple negative breast cancer. The company operates in the oncology segment, focusing on intratumoral and systemic delivery approaches to cancer therapy.
The company was incorporated in Delaware in 2012 and maintains its headquarters in Shelton, Connecticut. Intensity Therapeutics operates with a minimal employee base of five full-time staff members, reflecting the typical structure of clinical-stage biotechnology firms focused on development rather than commercial operations. The company is listed on Nasdaq, indicating it has completed the regulatory requirements for public market access despite its early revenue stage typical of pre-commercial clinical programs.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-1.17 | $-1.17 | +15.2% | |
| 2023 | $-1.38 | $-1.38 | — |